Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00344110 |
Assessing efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Aliskiren |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind, Placebo and Active-Controlled, Multicenter, Parallel-Group Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg to Evaluate Efficacy, Safety and Pharmacokinetics in Patients With Mild to Moderate Essential Hypertension |
Estimated Enrollment: | 743 |
Study Start Date: | June 2006 |
Ages Eligible for Study: | 20 Years to 75 Years |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Study ID Numbers: | CSPP100A1301 |
Study First Received: | June 22, 2006 |
Last Updated: | December 21, 2007 |
ClinicalTrials.gov Identifier: | NCT00344110 |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Hypertension, aliskiren, blood pressure, renin |
Losartan Vascular Diseases Essential hypertension Hypertension |
Cardiovascular Diseases |